Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will ...

The Phase III trial, testing the drug in patients whose cancers are Philadelphia chromosome-positive, will expand to the US and Europe.

AACR held an event on Capitol Hill with the NCI director and a legislator to discuss government efforts to support pediatric cancer research.

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President ...

A group of vaccine advisers to U.S. Health Secretary Robert F. Kennedy Jr. on Friday voted to remove the broad recommendation ...

Finally, Merck is an excellent dividend stock. It offers a juicy forward yield of 3.2% and has increased its payouts by 93.8% ...

This Auburn student shared how her summer internship led to a job offer from one of the largest pharmaceutical companies in the world 🎓 NowPartner #auburnuniversity #harbertcollegeofbuisness #auburnh ...

Delving into the opportunities for PE firms – including Diversis, GHO, InTandem and Summit Partners – to invest in healthcare ...

This data is from SOTA-P-CARDIA, a prospective, randomized, double-blind, placebo-controlled trial that exclusively enrolled patients with heart failure with preserved ejection fraction (HFpEF) and ...

Diversis, GHO, InTandem, Stone Point and Summit Partners are investing in services aimed at helping healthcare providers ...

A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's ...